Shots:
- Coave to receive $11.7M up front & equity investment, ~ $76.5M as clinical development, regulatory & commercial milestones along with royalties on net sales of the product. Both companies will co-develop Coave’s CTx-PDE6b & share the development costs
- Théa obtains an exclusive license to commercialize the therapy in the EU, Ukraine, Turkey, Russia, and North Africa. Coave retains the rights to commercialize CTx-PDE6b in the US
- CTx-PDE6b is a novel AAV-based gene therapy that is designed to deliver a non-mutated copy of the PDE6b gene into the subretinal space. The therapy is currently being evaluated in the P-I/II trial to determine its safety & efficacy
Click here to read full press release/ article | Ref: PR Newswire | Image: Coave Therapeutics
The post Coave Signs an Exclusive License Agreement with Théa to Co-Development and Commercialize CTx-PDE6b for PDE6b Associated Retinitis Pigmentosa in EU first appeared on PharmaShots.
